May 17, 2020

EHR Adoption Moving Quickly in US

Electronic Health Record System
primary care physicians
US
Admin
2 min
Doctors Start to Adapt to EHR Systems
Electronic Health Record (EHR) adoption rates appear to be well ahead of the US Congressional Budget Office (CBO) estimates. In 2009 the US Congression...

Electronic Health Record (EHR) adoption rates appear to be well ahead of the US Congressional Budget Office (CBO) estimates. In 2009 the US Congressional Budget Office estimated that the Health Information Technology for Economic and Clinical Health Act would result in roughly 90 per cent of doctors and 70 per cent of hospitals would be using a comprehensive EHR system by 2019. The health care industry is far ahead of the CBO’s timetable.

Since 2005, EHR adoption by family physicians has doubled. Researchers estimate that by the end of 2013 that number will exceed 80 per cent. In July 2012 the CDC’s Center for National Health Statistics reported just over 50 per cent office-based physicians had adapted to HER’s.

The Annals of Family Medicine published a study that noted that EHR adoption by family physicians varies from state-to-state and among different types of physicians. The report indicates adoption rates for family physicians were significantly higher than for other office-based physicians and rates ranged from as low as 47.1% in North Dakota to a high of 94.9% in Utah.

Getting patients on-board with new technology can be a hurdle for some physicians. According to a recent Forbes article by John Nosta, for patients to fully embrace new innovations, it all comes down to “doctor’s orders.” Nosta outlines several core strategies that digital health should embrace to help the average patient take a more active role in managing their health. Among the points, awareness of the technology ranks first.

Among the countries leading in EHR technology the US falls short far behind countries such as the Netherlands and New Zealand. 

Additional Resources:

Share article

Jun 23, 2021

Introducing Dosis - the AI powered dosing platform

AI
medication
personalisedmedicine
chronicdisease
3 min
Dosis is an AI-powered personalised medication dosing platform that's on a mission to transform chronic disease management

Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works. 

When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing. 

The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced. 

What is the Strategic Anemia Advisor? 
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease. 

SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool. 

What else is Dosis working on? 
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs. 

What are Dosis' strategic goals for the next 2-3 years? 
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.

What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.

Share article